Chemoimmunotherapy for melanoma with dacarbazine and 2,4-dinitrochlorobenzene elicits a specific T cell-dependent immune response

Cancer Immunology, Immunotherapy

Volumn 51, Issue 8, 2002, Pages 431-439

  Wack, Christiane ^a   Kirst, Annette ^a   Becker, Jürgen C ^a   Lutz, Werner K ^a   Bröcker, Eva B ^a   Fischer, Wolfgang H ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Cytotoxicity; T lymphocyte; Tumor immunity

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; CD4 ANTIGEN; CD8 ANTIGEN; CROTON OIL; CYTOKINE; DACARBAZINE; GAMMA INTERFERON; INTERLEUKIN 6; IRRITANT AGENT; MESSENGER RNA; TRIBUTYLIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CELL ACTIVITY; CELL ASSAY; CELL LINE; CONTROLLED STUDY; CYTOLYSIS; FEMALE; IMMUNE DEFICIENCY; IMMUNE RESPONSE; LUNG METASTASIS; LYMPHOCYTE; MELANOMA; MOUSE; MOUSE STRAIN; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA ANALYSIS; SENSITIZATION; SKIN TUMOR; SPLEEN; T LYMPHOCYTE; TAIL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR IMMUNOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; COMBINED MODALITY THERAPY; DACARBAZINE; DINITROCHLOROBENZENE; IMMUNOTHERAPY; IRRITANTS; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; RIBONUCLEASES; RNA, MESSENGER; T-LYMPHOCYTES; TIME FACTORS; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036042539     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-002-0292-4     Document Type: Article

References (63)

1. Immunologic features of progression in melanoma
2. Maintenance of clonal anergy by endogenously produced IL-10
3. T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin-2 therapy
4. Inhibition of murine lymphoma growth by adoptive transfer of lymphocytes sensitized to a xenogenized tumor variant
5. Immunological alteration of leukemic cells in vivo after treatment with an antitumor drug
6. Inflammatory cell infiltrates in human melanoma at different stages of tumor progression
7. Microcytotoxicity test in allograft immunity
8. Natural history of HLA expression during tumor development
9. Origin, maturation, and antigen presenting function of dendritic cells
10. Phase III multicenter randomized trial of the Darmouth regimen versus dacarbazine in patients with metastatic melanoma
11. Rejection of K1735 murine melanoma in syngeneic hosts require expression of MHC class I antigens and either class II antigens or IL-2
12. Production of IL-10 by melanoma cells: Examination of its role in immunosuppression mediated by melanoma
13. Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells
14. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
15. Loss of HLA class I antigens by melanoma cells
16. + T cells in the immune response to melanoma
17. Natural adjuvants: Endogenous activators of dendritic cells
18. Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma
19. Immunoregulatory mechanisms involved in elicitation of allergic contact hypersensitivity
20. + tumor-infiltrating lymphocytes in human solid tumors
21. Adoptive T cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells
22. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens
23. + T cells in the antitumor immune response
24. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses
25. The emerging role of cytokines in the treatment of advanced melanoma
26. Addition of dacarbazine or cisplatin to IFN-α/IL-2 in metastatic melanoma: Toxicity and immunological effects
27. T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas
28. Remission of melanoma with DNCB treatment
29. + cytotoxic T cells in association with histocompatibility leukocyte antigen DR11
30. + T lymphocytes
31. Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elict protective and therapeutic anti-tumor activity
32. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes
33. Kinetics of cytokine expression in melanoma metastases classifies immune responsiveness
34. A unique tumor antigen produced by a single amino acid substitution
35. + T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ
36. Cytokines, tumour-cell death and immunogenicity: A question of choice
37. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
38. Antigenic changes of L5178Y lymphoma after treatment with 5-(3,3 dimethyl-1-triazeno)imidazole-4-carboxamide in vivo
39. Specific T helper requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors
40. Rejection of mouse sarcoma cells after transfection of MHC class II genes
41. Escape from host-antitumor immunity
42. + T cells
43. Sequential dacarbazine/cisplatin and interleukin-2 in metastatic melanoma: Immunological effects of therapy
44. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
45. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin-2
46. Consequences of cell death: Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells
47. Targeting of lymphotoxin-α to the tumor elicts an efficient immune response associated with induction of peripheral lymphoid-like tissue
48. Immunotherapy of melanoma
49. The dendritic cell system and its role in immunogenicity
50. Topical dinitrochlorbenzene combined with systemic dacarbazine in the treatment of current melanoma
51. Transforming growth factor beta-induced inhibition of T cell function: Suceptibility differences in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state
52. + T lymphocytes against human melanoma. Evidence for a shared melanoma antigen presented by HLA-DR15
53. CD4 T cells kill melanoma cells by mechanisms that are independent of FAS (CD95)
54. In situ T cells in melanoma
55. Activation of preexisting T cell clones by targeted interleukin-2 therapy
56. Vaccination with MAGE-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
57. CD4 T cells and their role in antitumor responses
58. Aktivierungsmarker auf peripheren T-Lymphozyten beim metastasierten melanom unter kombinierter immunchemotherapie mit dinitrochlorbenzol (DNCB) lokal und dacarbazin (DTIC) systemisch - Beobachtungen an zwei fällen
59. Immunchemotherapie mit epifokaler applikation von dinitrochlorbenzol (DNCB) und systemischer chemotherapie mit dacarbazin (DTIC) beim metastasierenden melanom
60. Level of HLA antigen in locoreginal metastases in clinical course of the disease in patients with melanoma
61. Chemoimmunotherapy for melanoma with dacarbazine and 2,4-dinitrochlorbenzene: Results from a murine tumour model
62. Immune response against human primary malignant melanoma: A distinct cytokine mRNA profile associated with spontaneous regression
63. + T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus